1 insider bought €1.2M of shares over the last 90 days, the latest by 미래아이앤지, filed 14 Aug 2026.
KBIO LABS Inc.: what insiders have been doing
KBIO LABS Inc. belongs to the Health Care sector. Filings by its managers are published through DART (FSS). From 2 November 2025 to 2 November 2026, the disclosure feed for KBIO LABS Inc. logged 9 filings by 4 insiders.
Both sides are active: 3 purchases and 4 sales, from 1 insider and 3 insiders respectively. The totals do not cover 7 filings with an undisclosed amount. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The buyers include 1 major shareholder.
With 9 filings in twelve months, the company is more active than the median of 7 filings across the 2,655 companies we follow on the same exchange. Since 2021, the database holds 7 purchases and 26 sales by insiders of the company.
The clock since the last published purchase (14 August 2026) now reads 87 days. The median gap between a trade and its publication by DART (FSS) is 7 days. That lag is the time during which only the insider knows about the trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
In the same sector, recent insider purchases at Dynavox Group AB and UCB also feature in our signals. Every figure here comes from the filings published by DART (FSS) and describes the past, not future prices; it is not investment advice.
Who traded when
BuySaleSince the insiders bought
- -3.7%Entry ₩754 · Close at T+90 ₩726
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- Other0DART
- 8,490,250 sharesShareKRXDART:20260904000506
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- Other0DART
- 359,096 sharesShareKRXDART:20260814003030Canonical exit: 12 Nov 2026 (T+90)
- Other0DART
- Other0DART
- 2,747,253 sharesShareKRXDART:20260716000673Canonical exit: 14 Oct 2026 (T+90)
- 1,472,290 sharesKRXDART:20260716000666Canonical exit: 14 Oct 2026 (T+90)
- ●Executives0DART
- 30,627,515 sharesKRXDART:20260423000516
- 25,527,660 sharesShareKRXDART:20260423000521
- 5,099,855 sharesShareKRXDART:20260423000545
- ●Executives0DART
- 30,627,515 sharesKRXDART:20230905000351
- 30,627,515 sharesKRXDART:20230725000286
- ShareKRXDART:20230725000311
- ●Executives0DART
- ●Executives0DART
- ●Executives0DART
- 68,867 shares@ ₩335.003.7% of flowShareKRXDART:20230303000413Canonical exit: 29 May 2023 (T+90)
- 68,867 sharesKRXDART:20230303000399Canonical exit: 1 Jun 2023 (T+90)
25 of 54 declarations
About KBIO LABS Inc.
케이바이오랩스 is a company in the healthcare and pharmaceutical sector, listed on the XKRX market. It focuses on developing innovative solutions for the medical field.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
